Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Arrhythmogenic right ventricular cardiomyopathy 💬
 1件: ITGA4 💬 D06886 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
2 Biosynthesis of cofactors 💬
 1件: DHODH 💬 D10172 💬 Teriflunomide 3件: 13, 25, 26 💬
3 Cell adhesion molecules 💬
 1件: ITGA4 💬 D06886 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
4 Cell adhesion molecules 💬
 1件: PDCD1 💬 D10574 💬 Pembrolizumab 2件: 25, 285 💬
5 Coronavirus disease - COVID-19 💬
 2件: IFNAR1, IFNAR2 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
6 Coronavirus disease - COVID-19 💬
 2件: IFNAR1, IFNAR2 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
7 Cytokine-cytokine receptor interaction 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 35件:  2 ,  6 , 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
8 Cytokine-cytokine receptor interaction 💬
 2件: IFNAR1, IFNAR2 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
9 Cytokine-cytokine receptor interaction 💬
 2件: IFNAR1, IFNAR2 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
10 Dilated cardiomyopathy 💬
 1件: ITGA4 💬 D06886 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
11 ECM-receptor interaction 💬
 1件: ITGA4 💬 D06886 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
12 Epstein-Barr virus infection 💬
 2件: IFNAR1, IFNAR2 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
13 Epstein-Barr virus infection 💬
 2件: IFNAR1, IFNAR2 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
14 Focal adhesion 💬
 1件: ITGA4 💬 D06886 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
15 Hematopoietic cell lineage 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 35件:  2 ,  6 , 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
16 Hematopoietic cell lineage 💬
 1件: ITGA4 💬 D06886 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
17 Hepatitis B 💬
 1件: IFNAR1 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
18 Hepatitis B 💬
 1件: IFNAR1 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
19 Hepatitis C 💬
 2件: IFNAR1, IFNAR2 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
20 Hepatitis C 💬
 2件: IFNAR1, IFNAR2 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
21 Herpes simplex virus 1 infection 💬
 2件: IFNAR1, IFNAR2 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
22 Herpes simplex virus 1 infection 💬
 2件: IFNAR1, IFNAR2 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
23 Human papillomavirus infection 💬
 2件: IFNAR1, IFNAR2 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
24 Human papillomavirus infection 💬
 2件: IFNAR1, IFNAR2 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
25 Human papillomavirus infection 💬
 1件: ITGA4 💬 D06886 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
26 Hypertrophic cardiomyopathy 💬
 1件: ITGA4 💬 D06886 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
27 Influenza A 💬
 2件: IFNAR1, IFNAR2 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
28 Influenza A 💬
 2件: IFNAR1, IFNAR2 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
29 Intestinal immune network for IgA production 💬
 1件: ITGA4 💬 D06886 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
30 JAK-STAT signaling pathway 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 35件:  2 ,  6 , 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
31 JAK-STAT signaling pathway 💬
 2件: IFNAR1, IFNAR2 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
32 JAK-STAT signaling pathway 💬
 2件: IFNAR1, IFNAR2 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
33 Kaposi sarcoma-associated herpesvirus infection 💬
 2件: IFNAR1, IFNAR2 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
34 Kaposi sarcoma-associated herpesvirus infection 💬
 2件: IFNAR1, IFNAR2 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
35 Leishmaniasis 💬
 1件: ITGA4 💬 D06886 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
36 Leukocyte transendothelial migration 💬
 1件: ITGA4 💬 D06886 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
37 Measles 💬
 2件: IFNAR1, IFNAR2 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
38 Measles 💬
 2件: IFNAR1, IFNAR2 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
39 Metabolic pathways 💬
 1件: DHODH 💬 D10172 💬 Teriflunomide 3件: 13, 25, 26 💬
40 Natural killer cell mediated cytotoxicity 💬
 2件: IFNAR1, IFNAR2 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
41 Natural killer cell mediated cytotoxicity 💬
 2件: IFNAR1, IFNAR2 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
42 Necroptosis 💬
 2件: IFNAR1, IFNAR2 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
43 Necroptosis 💬
 2件: IFNAR1, IFNAR2 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
44 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00407 💬 Methylprednisolone 46件:  2 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
45 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00472 💬 Prednisolone 42件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
46 NOD-like receptor signaling pathway 💬
 2件: IFNAR1, IFNAR2 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
47 NOD-like receptor signaling pathway 💬
 2件: IFNAR1, IFNAR2 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
48 Osteoclast differentiation 💬
 2件: IFNAR1, IFNAR2 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
49 Osteoclast differentiation 💬
 2件: IFNAR1, IFNAR2 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
50 Pathways in cancer 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 35件:  2 ,  6 , 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
51 Pathways in cancer 💬
 2件: IFNAR1, IFNAR2 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
52 Pathways in cancer 💬
 2件: IFNAR1, IFNAR2 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
53 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: PDCD1 💬 D10574 💬 Pembrolizumab 2件: 25, 285 💬
54 PI3K-Akt signaling pathway 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 35件:  2 ,  6 , 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
55 PI3K-Akt signaling pathway 💬
 2件: IFNAR1, IFNAR2 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
56 PI3K-Akt signaling pathway 💬
 2件: IFNAR1, IFNAR2 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
57 PI3K-Akt signaling pathway 💬
 1件: ITGA4 💬 D06886 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
58 Pyrimidine metabolism 💬
 1件: DHODH 💬 D10172 💬 Teriflunomide 3件: 13, 25, 26 💬
59 Regulation of actin cytoskeleton 💬
 1件: ITGA4 💬 D06886 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬
60 T cell receptor signaling pathway 💬
 1件: PDCD1 💬 D10574 💬 Pembrolizumab 2件: 25, 285 💬
61 Toll-like receptor signaling pathway 💬
 2件: IFNAR1, IFNAR2 💬 D03305 💬 Interferon alfa 6件: 13, 25, 26, 28, 56, 96 💬
62 Toll-like receptor signaling pathway 💬
 2件: IFNAR1, IFNAR2 💬 D02745 💬 Interferon alfa-2b 2件: 25, 34 💬
63 Yersinia infection 💬
 1件: ITGA4 💬 D06886 💬 Natalizumab 6件: 13, 15, 25, 46, 63, 96 💬

先頭へ